{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:59:36Z","timestamp":1787702376177,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4t Augsburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Seroma formation is a frequent complication following mastectomy in the surgical treatment of breast cancer with profound consequences for the patients including possibly quality of life impairing implant complications. The pathogenesis remains unknown, leading to a lack of efficient preventive and curative strategies. The study\u2019s objective was to determine whether the macrophage infiltration of the tumor microenvironment and surrounding adipose tissue at the time of primary surgery is associated with postoperative seroma development. The observational monocentric SerMa pilot study was conducted from 12\/2019 to 12\/2022. We included 91 breast cancer and 9 carcinoma in situ cases treated with mastectomy at the University Hospital Augsburg, Germany. Patients with previous malignancies, metastatic disease and known immunodeficiency were excluded. The patients underwent different mastectomy procedures with or without implant- or expander-based breast reconstruction. The study\u2019s main outcome was seroma formation up to six months post-surgery, determined by clinical examination and fine needle aspiration of the seroma fluid if clinically necessary. Macrophage markers (CD68 and CD163) were immunohistochemically determined in formalin fixed paraffin-embedded slides containing the primary tumor and surrounding adipose tissue. Two groups were then formed as independent variables: cases with (seroma\u2009+) and without postoperative seroma formation (seroma-). Since all parameters in this study were not normally distributed, the non-parametric Mann\u2013Whitney-U-test was used. A p-value\u2009&lt;\u20090.05 was considered statistically significant. CD68\u2009+\u2009cells (cases with seroma (seroma\u2009+): median\u2009=\u200990.7 cells, IQR\u2009=\u200962.5\u2013130.5; cases without seroma (seroma-): median\u2009=\u200964.3 cells, IQR\u2009=\u200947.0\u2013115-0, p\u2009=\u20090.036) and CD163\u2009+\u2009cells (seroma\u2009+\u2009: median\u2009=\u200958.3 cells, IQR\u2009=\u200933.0\u201391.4; seroma-: median\u2009=\u200940.7 cells, IQR\u2009=\u200928.3\u201355.3, p\u2009=\u20090.027) in the tumor microenvironment and in the surrounding adipose tissue (CD68\u2009+\u2009cells (seroma\u2009+\u2009: median\u2009=\u20098.0 cells, IQR\u2009=\u20095.3\u201311.0; seroma-: median\u2009=\u20094.7 cells, IQR\u2009=\u20093.0\u201310.0, p\u2009=\u20090.013), CD163\u2009+\u2009cells (seroma\u2009+\u2009: median\u2009=\u200911.0 cells, IQR\u2009=\u20096.7\u201315.0; seroma-: median\u2009=\u20096.7 cells, IQR\u2009=\u20093.0\u20139.7, p\u2009=\u20090.016)) were significantly higher in cases with postoperative seroma formation compared to cases without. In the SerMa pilot study macrophage polarization within the primary tumor and surrounding adipose tissue was associated with post-operative seroma formation in breast cancer patients. This might be a suitable biomarker for predicting a higher risk of seroma formation.<\/jats:p>","DOI":"10.1038\/s41598-025-17139-2","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:57:00Z","timestamp":1757667420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Macrophage polarization is associated with postoperative seroma development in breast cancer in the SerMa pilot cohort"],"prefix":"10.1038","volume":"15","author":[{"given":"Felicitas Magdalena","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pochert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritzi","family":"Schittek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melitta Beatrice","family":"K\u00f6pke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Mathis","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Marie","family":"Veh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Renate","family":"Rohrmoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Henning","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Mattmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig Christian","family":"Hinske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Fluhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika M.","family":"Golas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Traidl-Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dannecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ditsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"4","key":"17139_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s13304-021-01049-9","volume":"73","author":"N Velotti","year":"2021","unstructured":"Velotti, N., Limite, G., Vitiello, A., Berardi, G. & Musella, M. Flap fixation in preventing seroma formation after mastectomy: An updated meta-analysis. Updates Surg. 73 (4), 1307\u20131314 (2021).","journal-title":"Updates Surg."},{"issue":"1","key":"17139_CR2","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1038\/s41598-022-13831-9","volume":"12","author":"C Adrien","year":"2022","unstructured":"Adrien, C. et al. Prevention of lymphocele or seroma after mastectomy and axillary lymphadenectomy for breast cancer: Systematic review and meta-analysis. Sci. Rep. 12 (1), 10016 (2022).","journal-title":"Sci. Rep."},{"issue":"4","key":"17139_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4048\/jbc.2012.15.4.373","volume":"15","author":"V Srivastava","year":"2012","unstructured":"Srivastava, V., Basu, S. & Shukla, V. K. Seroma formation after breast cancer surgery: What we have learned in the last two decades. J. Breast Cancer 15 (4), 373\u2013380 (2012).","journal-title":"J. Breast Cancer"},{"issue":"4","key":"17139_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2325\/jbcs.12.288","volume":"12","author":"K Kuroi","year":"2005","unstructured":"Kuroi, K. et al. Pathophysiology of seroma in breast cancer. Breast Cancer 12 (4), 288\u2013293 (2005).","journal-title":"Breast Cancer"},{"issue":"1","key":"17139_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.imlet.2010.03.002","volume":"131","author":"E Montalto","year":"2010","unstructured":"Montalto, E. et al. Seroma fluid subsequent to axillary lymph node dissection for breast cancer derives from an accumulation of afferent lymph. Immunol. Lett. 131 (1), 67\u201372 (2010).","journal-title":"Immunol. Lett."},{"issue":"1","key":"17139_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/110241599750007441","volume":"165","author":"J Bonnema","year":"1999","unstructured":"Bonnema, J., Ligtenstein, D. A., Wiggers, T. & van Geel, A. N. The composition of serous fluid after axillary dissection. Eur. J. Surg. 165 (1), 9\u201313 (1999).","journal-title":"Eur. J. Surg."},{"issue":"5","key":"17139_CR7","first-page":"487","volume":"36","author":"S Watt-Boolsen","year":"1989","unstructured":"Watt-Boolsen, S., Nielsen, V. B., Jensen, J. & Bak, S. Postmastectomy seroma. A study of the nature and origin of seroma after mastectomy. Dan. Med. Bull. 36 (5), 487\u20139 (1989).","journal-title":"Dan. Med. Bull."},{"issue":"3","key":"17139_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1054\/brst.1999.0126","volume":"9","author":"JA McCaul","year":"2000","unstructured":"McCaul, J. A. et al. Aetiology of seroma formation in patients undergoing surgery for breast cancer. Breast 9 (3), 144\u2013148 (2000).","journal-title":"Breast"},{"issue":"14","key":"17139_CR9","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.3390\/cancers15143606","volume":"15","author":"MB Kopke","year":"2023","unstructured":"Kopke, M. B. et al. Elderly and patients with large breast volume have an increased risk of seroma formation after mastectomy-results of the SerMa pilot study. Cancers (Basel) 15 (14), 3606 (2023).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"17139_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5114\/aoms.2012.29219","volume":"9","author":"J Zielinski","year":"2013","unstructured":"Zielinski, J., Jaworski, R., Irga, N., Kruszewski, J. W. & Jaskiewicz, J. Analysis of selected factors influencing seroma formation in breast cancer patients undergoing mastectomy. Arch. Med. Sci. 9 (1), 86\u201392 (2013).","journal-title":"Arch. Med. Sci."},{"issue":"5","key":"17139_CR11","first-page":"292","volume":"40","author":"S Kumar","year":"1995","unstructured":"Kumar, S., Lal, B. & Misra, M. C. Post-mastectomy seroma: A new look into the aetiology of an old problem. J. R. Coll Surg. Edinb. 40 (5), 292\u2013294 (1995).","journal-title":"J. R. Coll Surg. Edinb."},{"issue":"9","key":"17139_CR12","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.3390\/ijms23094848","volume":"23","author":"N Pochert","year":"2022","unstructured":"Pochert, N. et al. Seroma after simple mastectomy in breast cancer-the role of CD4+ T helper cells and the evidence as a possible specific immune process. Int. J. Mol. Sci. 23 (9), 4848 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"17139_CR13","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00404-023-07074-w","volume":"308","author":"N Pochert","year":"2023","unstructured":"Pochert, N. et al. Th2\/Th17 cell associated cytokines found in seroma fluids after breast cancer surgery. Arch. Gynecol. Obstet. 308 (5), 1621\u20131627 (2023).","journal-title":"Arch. Gynecol. Obstet."},{"issue":"1","key":"17139_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-021-01422-x","volume":"23","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). Breast Cancer Res. 23 (1), 45 (2021).","journal-title":"Breast Cancer Res."},{"key":"17139_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566511","volume":"10","author":"I Larionova","year":"2020","unstructured":"Larionova, I. et al. Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers. Front. Oncol. 10, 566511 (2020).","journal-title":"Front. Oncol."},{"key":"17139_CR16","doi-asserted-by":"publisher","first-page":"tkac057","DOI":"10.1093\/burnst\/tkac057","volume":"11","author":"C Chen","year":"2023","unstructured":"Chen, C. et al. Epigenetic regulation of macrophage polarization in wound healing. Burns Trauma 11, tkac057 (2023).","journal-title":"Burns Trauma"},{"issue":"2","key":"17139_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/wound.2012.0362","volume":"2","author":"A Leask","year":"2013","unstructured":"Leask, A. The contribution of peroxisome proliferator-activated receptor gamma to cutaneous wound healing. Adv. Wound Care (New Rochelle). 2 (2), 69\u201373 (2013).","journal-title":"Adv. Wound Care (New Rochelle)."},{"issue":"2","key":"17139_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cellimm.2011.10.021","volume":"272","author":"ZK Al-Gaithy","year":"2012","unstructured":"Al-Gaithy, Z. K. & Ayuob, N. N. Vascular and cellular events in post-mastectomy seroma: An immunohistochemical study. Cell Immunol. 272 (2), 130\u2013136 (2012).","journal-title":"Cell Immunol."},{"key":"17139_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.actbio.2023.08.018","volume":"169","author":"O Protsepko","year":"2023","unstructured":"Protsepko, O. et al. Induction of a different immune response in non-titanized compared to titanized polypropylene meshes. Acta Biomater. 169, 363\u2013371 (2023).","journal-title":"Acta Biomater."},{"issue":"8","key":"17139_CR20","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1002\/jbm.b.34639","volume":"108","author":"U Klinge","year":"2020","unstructured":"Klinge, U., Dievernich, A., Tolba, R., Klosterhalfen, B. & Davies, L. CD68+ macrophages as crucial components of the foreign body reaction demonstrate an unconventional pattern of functional markers quantified by analysis with double fluorescence staining. J. Biomed. Mater. Res. B Appl. Biomater. 108 (8), 3134\u20133146 (2020).","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"17139_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585297","volume":"10","author":"S Qian","year":"2020","unstructured":"Qian, S. et al. Is sCD163 a clinical significant prognostic value in cancers? A systematic review and meta-analysis. Front. Oncol. 10, 585297 (2020).","journal-title":"Front. Oncol."},{"issue":"3","key":"17139_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000538596","volume":"19","author":"TW Park-Simon","year":"2024","unstructured":"Park-Simon, T. W. et al. Arbeitsgemeinschaft gynakologische onkologie recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2024. Breast Care (Basel) 19 (3), 165\u2013182 (2024).","journal-title":"Breast Care (Basel)"},{"issue":"5","key":"17139_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","volume":"32","author":"S Gordon","year":"2010","unstructured":"Gordon, S. & Martinez, F. O. Alternative activation of macrophages: Mechanism and functions. Immunity 32 (5), 593\u2013604 (2010).","journal-title":"Immunity"},{"issue":"6","key":"17139_CR24","doi-asserted-by":"publisher","first-page":"e002548","DOI":"10.1136\/jitc-2021-002548","volume":"9","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. S100A4 enhances protumor macrophage polarization by control of PPAR-gamma-dependent induction of fatty acid oxidation. J. Immunother. Cancer 9 (6), e002548 (2021).","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"17139_CR25","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3390\/cells11071244","volume":"11","author":"W Shao","year":"2022","unstructured":"Shao, W. et al. Cytoplasmic colocalization of RXRalpha and PPARgamma as an independent negative prognosticator for breast cancer patients. Cells 11 (7), 1244 (2022).","journal-title":"Cells"},{"key":"17139_CR26","doi-asserted-by":"publisher","first-page":"1205030","DOI":"10.3389\/fphar.2023.1205030","volume":"14","author":"L Li","year":"2023","unstructured":"Li, L. et al. Inhibition of PPARgamma by BZ26, a GW9662 derivate, attenuated obesity-related breast cancer progression by inhibiting the reprogramming of mature adipocytes into to cancer associate adipocyte-like cells. Front. Pharmacol. 14, 1205030 (2023).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"17139_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4014\/jmb.2309.09019","volume":"34","author":"NY Kim","year":"2024","unstructured":"Kim, N. Y., Park, H. M., Lee, H. P., Hong, J. T. & Yoon, D. Y. (E)-2-Methoxy-4-(3-(4-Methoxyphenyl) Prop-1-en-1-yl) phenol suppresses breast cancer progression by dual-regulating VEGFR2 and PPARgamma. J. Microbiol. Biotechnol. 34 (2), 240\u2013248 (2024).","journal-title":"J. Microbiol. Biotechnol."},{"issue":"3","key":"17139_CR28","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/ijms23031510","volume":"23","author":"A Kazberuk","year":"2022","unstructured":"Kazberuk, A., Chalecka, M., Palka, J. & Surazynski, A. Nonsteroidal anti-inflammatory drugs as PPARgamma agonists can induce PRODH\/POX-dependent apoptosis in breast cancer cells: New alternative pathway in NSAID-induced apoptosis. Int. J. Mol. Sci. 23 (3), 1510 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"17139_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4149\/neo_2020_190805N716","volume":"67","author":"XX Jiao","year":"2020","unstructured":"Jiao, X. X. et al. The inhibition of the breast cancer by PPARgamma agonist pioglitazone through JAK2\/STAT3 pathway. Neoplasma 67 (4), 834\u2013842 (2020).","journal-title":"Neoplasma"},{"issue":"1","key":"17139_CR30","doi-asserted-by":"publisher","first-page":"22988","DOI":"10.1038\/s41598-024-71962-7","volume":"14","author":"H Fu","year":"2024","unstructured":"Fu, H. et al. Cystathionine-gamma-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARgamma\/ACSL1\/STAT3 signalling pathway in oestrogen receptor-positive breast cancer. Sci. Rep. 14 (1), 22988 (2024).","journal-title":"Sci. Rep."},{"issue":"5","key":"17139_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.102059","volume":"32","author":"QH Alqahtani","year":"2024","unstructured":"Alqahtani, Q. H. et al. Pioglitazone enhances cisplatin\u2019s impact on triple-negative breast cancer: Role of PPARgamma in cell apoptosis. Saudi Pharm. J. 32 (5), 102059 (2024).","journal-title":"Saudi Pharm. J."},{"issue":"24","key":"17139_CR32","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.3390\/ijms21249721","volume":"21","author":"G Augimeri","year":"2020","unstructured":"Augimeri, G. et al. Natural and synthetic PPARgamma ligands in tumor microenvironment: A new potential strategy against breast cancer. Int. J. Mol. Sci. 21 (24), 9721 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"17139_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4049\/jimmunol.1000413","volume":"185","author":"G Solinas","year":"2010","unstructured":"Solinas, G. et al. Tumor-conditioned macrophages secrete migration-stimulating factor: A new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 185 (1), 642\u2013652 (2010).","journal-title":"J. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17139-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17139-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:04:08Z","timestamp":1758056648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17139-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17139"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17139-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"They reported to have received fees as follows: N.D.: Advisory Boards and speakers bureaus AstraZeneca, Aurikamed, BGGF, Daiichi-Sankyo, Elsevier Verlag, ESO, Exact Sciences, Gilead Sciences, GSK, if-Kongress, KelCon, Leopoldina Schweinfurt, Lilly, Lukon, Molekular Health, MSD, Novartis, onkowissen, Pfizer, RG-\u00c4rztefortbildungen, Roche, Seagen. K.-H.K.: Advisory Boards and speakers bureaus AstraZeneca, MSD, BMS, Merck, Roche, Sanofi-Aventis, Icotec, Varian, Carl Zeiss Meditec AG and ELEKTA. M.B.-P.: Fees for lectures and consulting activities: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, resitu, Pierre Fabre, ExactSciences; Study support: EndoMag, Mammotome, MeritMedical, Sirius Medical, Gilead, Hologic, ExactSciences, Claudia von Schilling Stiftung, Damp Stiftung, Ehmann Stiftung Savognin; Coverage of travel and congress costs: Eli Lilly, ExactSciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche, Stemline. C.D.: Roche, AstraZeneca, TEVA, Mentor, and MCI Healthcare. R.F.: Elsevier Verlag. C.M.W.: Novartis, BGGF, if-Kongrss, RG Gesellschaft f\u00fcr Information und Organisation. M.B.K.: speaker honorars from Eisai GmbH, AstraZeneca, Aurikamed, Novartis, coverage of travel and congress costs: MSD Sharp&Dohme GmbH, Lilly GmbH, the other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol was approved by the Ethics Committee of Ludwig-Maximilian-University (Munich) (approval 20-0953; 04.03.2021). Informed consent was given by all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"32442"}}